3-甲基丁基氨基(苯基)乙酸酯盐酸盐 | 31031-74-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-甲基丁基氨基(苯基)乙酸酯盐酸盐
• 中文别名: 苯基氨基乙酸盐酸盐异戊基；2-苯基甘氨酸盐酸盐异戊基；2-氨；3-甲基丁基2-氨基-2-苯基乙酸酯盐酸盐；2-氨基-2-苯基乙酸异戊酯盐酸盐；2-氨基-2-苯基-乙酸盐酸盐异戊基；苯基氨基乙酸异戊基酯盐酸盐
• 英文名称: Phenamazid
• 英文别名: Phenamacidum hydrochloricum；amino-phenyl-acetic acid isopentylester; hydrochloride；Amino-phenyl-essigsaeure-isopentylester; Hydrochlorid；Isopentyl amino(phenyl)acetate hydrochloride；3-methylbutyl 2-amino-2-phenylacetate;hydrochloride
• CAS: 31031-74-0
• 化学式: C₁₃H₁₉NO₂*ClH
• 分子量: 257.76
• InChiKey: PPBQUBHHPSGLBN-UHFFFAOYSA-N

物化性质

• 熔点：
  154°

计算性质

• 辛醇/水分配系数(LogP)：
  -1.44
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  53.9
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为产物：
  描述：

  异戊醇 、 2-氨基-2-苯基乙酸 以88%的产率得到3-甲基丁基氨基(苯基)乙酸酯盐酸盐
  参考文献：
  名称：

  Schulz; Sprung; Kroning, Pharmazie, 1983, vol. 38, # 5, p. 310 - 313

  摘要：

  DOI：

文献信息

• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders
  申请人：Fraser Oliver Matthew

  公开号：US20050113421A1

  公开（公告）日：2005-05-26

  A method is provided for using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat non-inflammatory gastrointestinal tract disorders.

  提供了一种方法，用于使用Cav2.2亚单位钙通道调节剂，特别是噻唑啉酮、噁唑啉酮和咪唑啉酮衍生物，来治疗非炎症性胃肠道疾病。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。
• Transdermal device containing polyvinylpyrrolidone as solubility enhancer
  申请人：NOVEN PHARMACEUTICALS, INC.

  公开号：EP1329225A2

  公开（公告）日：2003-07-23

  A blend of at least three polymers, including a soluble polyvinylpyrrolidone, in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. Soluble polyvinylpyrrolidone increases the solubility of drug without negatively affecting the adhesivity of the composition or the rate of drug delivery from the pressure-sensitive adhesive composition

  包括可溶性聚乙烯吡咯烷酮在内的至少三种聚合物与药物的混合物为透皮给药系统提供了一种压敏粘合剂组合物，当压敏粘合剂组合物与人体皮肤接触时，药物可从压敏粘合剂组合物中通过真皮输送。可溶性聚乙烯吡咯烷酮增加了药物的溶解度，而不会对组合物的粘附性或压敏胶组合物的给药速率产生负面影响。